Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
Tóm tắt
This phase II trial was initiated to assess the efficacy and safety of oral vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Eligible patients must have recurrent and/or metastatic head and neck cancer unresponsive to or intolerant of conventional chemotherapy. Patients must have measurable disease, adequate hematologic, hepatic, and renal function, and be able to swallow capsules. Four or more weeks must have elapsed since prior chemotherapy, radiation therapy, major surgery or investigational anticancer therapy, and patients must have recovered from prior toxicities. Study endpoints included response rate, duration of stable disease and progression-free survival. Thirteen patients were enrolled (9 males); 1 withdrew consent prior to starting therapy. Twelve patients received oral vorinostat 400 mg once daily and were evaluable for response. The median age was 54 years (range 40–82). All patients had received prior chemotherapy (including 10 with platinum- or taxane-based combination therapy), and 9 had prior radiation therapy. No confirmed partial or complete responses were observed. One unconfirmed partial response was seen. Three patients had stable disease ranging from 9 to 26 weeks. Nine patients discontinued due to progressive disease, two withdrew consent, and one discontinued therapy for grade 3 anorexia. Grades 3–4 drug-related toxicities included thrombocytopenia (n = 3), anorexia (n = 2), and dehydration (n = 2). Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients.
Tài liệu tham khảo
citation_journal_title=CA Cancer J Clin; citation_title=Cancer statistics, 2005; citation_author=A Jemal, T Murray, E Ward, A Samuels, RC Tiwari, A Ghafoor, EJ Feuer, MJ Thun; citation_volume=55; citation_publication_date=2005; citation_pages=10-30; citation_doi=10.3322/canjclin.55.1.10; citation_id=CR1
citation_journal_title=J Natl Cancer Inst.; citation_title=Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment; citation_author=BK Edwards, ML Brown, PA Wingo, HL Howe, E Ward, LA Ries, D Schrag, PM Jamison, A Jemal, XC Wu, C Friedman, L Harlan, J Warren, RN Anderson, LW Pickle; citation_volume=97; citation_publication_date=2005; citation_pages=1407-1427; citation_doi=10.1093/jnci/dji289; citation_id=CR2
citation_journal_title=J Clin Oncol; citation_title=Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology; citation_author=RS Herbst, DF Bajorin, H Bleiberg, D Blum, D Hao, BE Johnson, RF Ozols, GD Demetri, PA Ganz, MG Kris, B Levin, M Markman, D Raghavan, GH Reaman, R Sawaya, LM Schuchter, JW Sweetenham, LT Vahdat, EE Vokes, RJ Winn, RJ Mayer; citation_volume=24; citation_publication_date=2006; citation_pages=190-205; citation_doi=10.1200/JCO.2005.04.8678; citation_id=CR3
citation_journal_title=J Clin Oncol; citation_title=Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study; citation_author=B Burtness, MA Goldwasser, W Flood, B Mattar, AA Forastiere; citation_volume=23; citation_publication_date=2005; citation_pages=8646-8654; citation_doi=10.1200/JCO.2005.02.4646; citation_id=CR4
citation_journal_title=J Clin Oncol; citation_title=Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy; citation_author=A Argiris, Y Li, BA Murphy, CJ Langer, AA Forastiere; citation_volume=22; citation_publication_date=2004; citation_pages=262-268; citation_doi=10.1200/JCO.2004.08.039; citation_id=CR5
citation_journal_title=Nat Rev Cancer; citation_title=Histone deacetylases and cancer: causes and therapies; citation_author=P Marks, RA Rifkind, VM Richon, R Breslow, T Miller, WK Kelly; citation_volume=1; citation_publication_date=2001; citation_pages=194-202; citation_doi=10.1038/35106079; citation_id=CR6
citation_journal_title=J Clin Oncol; citation_title=Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies; citation_author=KN Bhalla; citation_volume=23; citation_publication_date=2005; citation_pages=3971-3993; citation_doi=10.1200/JCO.2005.16.600; citation_id=CR7
citation_journal_title=Anticancer Res; citation_title=Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment; citation_author=UH Weidle, A Grossmann; citation_volume=20; citation_publication_date=2000; citation_pages=1471-1485; citation_id=CR8
citation_journal_title=J Cell Biochem; citation_title=Prospects: histone deacetylase inhibitors; citation_author=M Dokmanovic, PA Marks; citation_volume=96; citation_publication_date=2005; citation_pages=293-304; citation_doi=10.1002/jcb.20532; citation_id=CR9
citation_journal_title=Int J Oncol; citation_title=Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma; citation_author=S Takumi, U Katsuhiro, O Takeshi, S Masashi, Y Hidetaka, S Takahiko, T Hideki; citation_volume=29; citation_publication_date=2006; citation_pages=117-124; citation_id=CR10
citation_journal_title=Proc Natl Acad Sci U S A; citation_title=A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases; citation_author=VM Richon, S Emiliani, E Verdin, Y Webb, R Breslow, RA Rifkind, PA Marks; citation_volume=95; citation_publication_date=1998; citation_pages=3003-3007; citation_doi=10.1073/pnas.95.6.3003; citation_id=CR11
citation_journal_title=Blood; citation_title=Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells; citation_author=R Nimmanapalli, L Fuino, C Stobaugh, V Richon, K Bhalla; citation_volume=101; citation_publication_date=2003; citation_pages=3236-3239; citation_doi=10.1182/blood-2002-08-2675; citation_id=CR12
citation_journal_title=Exp Hematol; citation_title=Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines; citation_author=S Sakajiri, T Kumagai, N Kawamata, T Saitoh, JW Said, HP Koeffler; citation_volume=33; citation_publication_date=2005; citation_pages=53-61; citation_doi=10.1016/j.exphem.2004.09.008; citation_id=CR13
citation_journal_title=J Biol Chem; citation_title=Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-{kappa}B activation; citation_author=Y Takada, A Gillenwater, H Ichikawa, BB Aggarwal; citation_volume=281; citation_publication_date=2006; citation_pages=5612-5622; citation_doi=10.1074/jbc.M507213200; citation_id=CR14
citation_journal_title=Clin Cancer Res; citation_title=Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2; citation_author=P Bali, M Pranpat, R Swaby, W Fiskus, H Yamaguchi, M Balasis, K Rocha, HG Wang, V Richon, K Bhalla; citation_volume=11; citation_publication_date=2005; citation_pages=6382-6389; citation_doi=10.1158/1078-0432.CCR-05-0344; citation_id=CR15
citation_journal_title=Clin Cancer Res; citation_title=Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro; citation_author=MC Kutko, RD Glick, LM Butler, DC Coffey, RA Rifkind, PA Marks, VM Richon, MP LaQuaglia; citation_volume=9; citation_publication_date=2003; citation_pages=5749-5755; citation_id=CR16
citation_journal_title=Cancer Res; citation_title=Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo; citation_author=LM Butler, DB Agus, HI Scher, B Higgins, A Rose, C Cordon-Cardo, HT Thaler, RA Rifkind, PA Marks, VM Richon; citation_volume=60; citation_publication_date=2000; citation_pages=5165-5170; citation_id=CR17
citation_journal_title=Anticancer Res; citation_title=Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors; citation_author=LA Cohen, PA Marks, RA Rifkind, S Amin, D Desai, B Pittman, VM Richon; citation_volume=22; citation_publication_date=2002; citation_pages=1497-1504; citation_id=CR18
citation_journal_title=J Clin Oncol; citation_title=Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer; citation_author=WK Kelly, OA O’Connor, LM Krug, JH Chiao, M Heaney, T Curley, B MacGregore-Cortelli, W Tong, JP Secrist, L Schwartz, S Richardson, E Chu, S Olgac, PA Marks, H Scher, VM Richon; citation_volume=23; citation_publication_date=2005; citation_pages=3923-3931; citation_doi=10.1200/JCO.2005.14.167; citation_id=CR19
citation_journal_title=Control Clin Trials; citation_title=Optimal two-stage designs for phase II clinical trials; citation_author=R Simon; citation_volume=10; citation_publication_date=1989; citation_pages=1-10; citation_doi=10.1016/0197-2456(89)90015-9; citation_id=CR20
citation_journal_title=J Clin Oncol; citation_title=Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck; citation_author=D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu; citation_volume=22; citation_publication_date=2004; citation_pages=77-85; citation_doi=10.1200/JCO.2004.06.075; citation_id=CR21
citation_journal_title=J Clin Oncol; citation_title=Cetuximab (Erbitux®) in recurrent/metstatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies; citation_author=J Vermorken, J Bourhis, J Trigo, M Kies, X Leon, M Mueser, N Amellal, A Scheler, J Baselga; citation_volume=23; citation_publication_date=2005; citation_pages=501s; citation_id=CR22
citation_journal_title=Cancer; citation_title=Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer; citation_author=MH Amer, M Al Sarraf, VK Vaitkevicius; citation_volume=43; citation_publication_date=1979; citation_pages=2202-2206; citation_doi=10.1002/1097-0142(197906)43:6<2202::AID-CNCR2820430607>3.0.CO;2-J; citation_id=CR23
citation_journal_title=J Clin Oncol; citation_title=Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck; citation_author=AD Colevas; citation_volume=24; citation_publication_date=2006; citation_pages=2644-2652; citation_doi=10.1200/JCO.2005.05.3348; citation_id=CR24
citation_journal_title=Clin Cancer Res; citation_title=Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck; citation_author=EE Cohen, MA Kane, MA List, BE Brockstein, B Mehrotra, D Huo, AM Mauer, C Pierce, A Dekker, EE Vokes; citation_volume=11; citation_publication_date=2005; citation_pages=8418-8424; citation_doi=10.1158/1078-0432.CCR-05-1247; citation_id=CR25
citation_journal_title=Eur J Cancer; citation_title=A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix; citation_author=JJ Knox, LL Siu, E Chen, J Dimitroulakos, S Kamel-Reid, MJ Moore, S Chin, J Irish, S LaFramboise, AM Oza; citation_volume=41; citation_publication_date=2005; citation_pages=523-530; citation_doi=10.1016/j.ejca.2004.12.013; citation_id=CR26
citation_journal_title=Cancer Investig; citation_title=Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group; citation_author=CJ Langer, Y Li, T Jennings, RC DeConti, S Nair, RB Cohen, AA Forastiere; citation_volume=22; citation_publication_date=2004; citation_pages=823-831; citation_doi=10.1081/CNV-200039628; citation_id=CR27
citation_journal_title=Eur J Cancer; citation_title=Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study; citation_author=F Duffaud, M Borner, P Chollet, JB Vermorken, J Bloch, M Degardin, F Rolland, C Dittrich, B Baron, D Lacombe, P Fumoleau; citation_volume=40; citation_publication_date=2004; citation_pages=2748-2752; citation_id=CR28
citation_journal_title=Invest New Drugs; citation_title=A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck; citation_author=DG Pfister, J McCaffrey, AJ Zahalsky, GK Schwartz, E Lis, W Gerald, A Huvos, J Shah, D Kraus, A Shaha, B Singh, S Wolden, M Zelefsky, I Palgi; citation_volume=20; citation_publication_date=2002; citation_pages=123-127; citation_doi=10.1023/A:1014449309165; citation_id=CR29
citation_journal_title=J Clin Oncol; citation_title=Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group; citation_author=MK Gibson, Y Li, B Murphy, MH Hussain, RC DeConti, J Ensley, AA Forastiere; citation_volume=23; citation_publication_date=2005; citation_pages=3562-3567; citation_doi=10.1200/JCO.2005.01.057; citation_id=CR30
citation_journal_title=Cancer Chemother Pharmacol; citation_title=Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study; citation_author=M Schena, C Barone, N Birocco, D Dongiovanni, G Numico, I Colantonio, O Bertetto; citation_volume=55; citation_publication_date=2005; citation_pages=271-276; citation_doi=10.1007/s00280-004-0875-1; citation_id=CR31
citation_journal_title=Oncology; citation_title=Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study; citation_author=F Caponigro, G Rosati, P Rosa, A Avallone, V Rosa, L Lucia, P Comella, G Comella; citation_volume=63; citation_publication_date=2002; citation_pages=232-238; citation_doi=10.1159/000065470; citation_id=CR32
citation_journal_title=J Clin Oncol; citation_title=Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group; citation_author=D Schrijvers, J Johnson, U Jiminez, M Gore, P Kosmidis, H Szpirglas, K Robbins, J Oliveira, R Lewensohn, J Schuller, A Riviere, C Arvay, P Langecker, H Jacob, E Cvitkovic, E Vokes; citation_volume=16; citation_publication_date=1998; citation_pages=1054-1059; citation_id=CR33
citation_journal_title=Cancer Res; citation_title=Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA; citation_author=MS Kim, M Blake, JH Baek, G Kohlhagen, Y Pommier, F Carrier; citation_volume=63; citation_publication_date=2003; citation_pages=7291-7300; citation_id=CR34
citation_journal_title=J Cancer Res Clin Oncol; citation_title=The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells; citation_author=M Ocker, A Alajati, M Ganslmayer, S Zopf, M Luders, D Neureiter, EG Hahn, D Schuppan, C Herold; citation_volume=131; citation_publication_date=2005; citation_pages=385-394; citation_doi=10.1007/s00432-004-0664-6; citation_id=CR35
citation_journal_title=Radiat Res; citation_title=Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors; citation_author=Y Zhang, M Jung, A Dritschilo, M Jung; citation_volume=161; citation_publication_date=2004; citation_pages=667-674; citation_doi=10.1667/RR3192; citation_id=CR36
Sgouros G, Yang WH, Richon VM, Kelly WK, Rifkind RA, Marks PA (2002) Synergistic interaction of suberoylanilide hydroxamic acid (SAHA) and radiation in human prostate cancer spheroids. Proc Am Soc Clin Oncol #105 (Abstract)
citation_journal_title=Int J Radiat Biol; citation_title=Chemical agents that promote chromatin compaction radiosensitize tumour cells; citation_author=S Biade, CC Stobbe, JT Boyd, JD Chapman; citation_volume=77; citation_publication_date=2001; citation_pages=1033-1042; citation_doi=10.1080/09553000110066068; citation_id=CR38
citation_journal_title=Oncol Res; citation_title=Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells; citation_author=G Ferrandina, P Filippini, C Ferlini, N Maggiano, AB Stoler, E Fruscella, S Mozzetti, S Mancuso, RS Freedman, G Scambia, FO Ranelletti; citation_volume=12; citation_publication_date=2000; citation_pages=429-440; citation_id=CR39
citation_journal_title=Int J Radiat Biol; citation_title=Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate; citation_author=AC Miller, T Whittaker, A Thibault, D Samid; citation_volume=72; citation_publication_date=1997; citation_pages=211-218; citation_doi=10.1080/095530097143437; citation_id=CR40
citation_journal_title=Mol Cancer Ther; citation_title=Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death; citation_author=RV Nome, A Bratland, G Harman, O Fodstad, Y Andersson, AH Ree; citation_volume=4; citation_publication_date=2005; citation_pages=1231-1238; citation_doi=10.1158/1535-7163.MCT-04-0304; citation_id=CR41
citation_journal_title=Radiat Res; citation_title=Novel HDAC inhibitors with radiosensitizing properties; citation_author=M Jung, A Velena, B Chen, PA Petukhov, AP Kozikowski, A Dritschilo; citation_volume=163; citation_publication_date=2005; citation_pages=488-493; citation_doi=10.1667/RR3345; citation_id=CR42
citation_journal_title=Clin Cancer Res; citation_title=Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity; citation_author=A Munshi, JF Kurland, T Nishikawa, T Tanaka, ML Hobbs, SL Tucker, S Ismail, C Stevens, RE Meyn; citation_volume=11; citation_publication_date=2005; citation_pages=4912-4922; citation_doi=10.1158/1078-0432.CCR-04-2088; citation_id=CR43
citation_journal_title=Mol Cancer Ther; citation_title=Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy; citation_author=YL Chung, AJ Wang, LF Yao; citation_volume=3; citation_publication_date=2004; citation_pages=317-325; citation_id=CR44